跳到主要內容區塊
搜尋

研究發展

:::

實驗室名稱:劉兆蓮老師研究室

主持人:劉兆蓮老師

Chao Lien Liu, Ph.D

Immunology, Oncology, Immunotherapy

Academic Title:

Assistant Professor,

School of Medical Laboratory Science and Biotechnology,

Taipei Medical University, Taiwan.

 

RESEARCH SUMMARY

Immunotherapeutic effects and their molecular mechanisms investigation for cancers and/or immunodeficiency treatments

 

CLINICAL INTERESTS

1. Cell therapies including gamma/delta T cells, CAR-T cells, regulatory T cells; Immunomodulation; Pancreatic cancers; Ovarian cancers and colon cancers

2. Ageing immunity

 

RESEARCH DESCRIPTION

Our long-term goal is to understand the molecular mechanisms of cell-cell interaction during immune cells cytotoxicity on cancers and the potential for clinical translational applications. Our laboratory aims to development of immunotherapy strategies/protocols for treating cancers and/or immunodeficiency diseases. In addition, using the tumor-xenograft humanized mouse model system, we want to uncover the important molecular mechanisms of immunotherapy as well as the in-vivo therapeutic immune responses. Currently, two prominent immunotherapy systems were investigated: gamma/delta T cells and chimeric antigen receptors (CARs) T cells.

 

1. Ex-vivo expanded gamma/delta T cells for treating cancers

I. We study the molecular mechanisms of gamma/delta T cells cytotoxicity activities and morphological changes first in ovarian cancers treatment. We have demonstrated that ex-vivo expanded gamma/delta T cells from human PBMCs showed potent cytotoxicity towards epithelial ovarian malignancy both in-vitro and in the tumor xenograft mice.  

 

II. In order to develop a best clinically feasible therapeutic method, we recently continue to optimize and modify different chimeric gamma/delta T cells as well as develop to target different types of cancers (ex: pancreatic cancers) to achieve the greatest enhancement in therapies. Next step will be to test the new chimeric gamma/delta T cells in the xenograft animal models.

 

2. Engineering chimeric antigen receptor (CAR) T-cells for treating Cancers

I. T cells engineered with chimeric antigen receptors (CARs) have been successfully applied in treating patients with advanced B cell malignancies but have not well done yet in treating solid tumors specifically in the clinical trials. Our laboratory is taking several CARs approaches to combat different solid tumors, for example: ovarian and pancreatic cancers. Moreover, the molecular mechanisms as well as the therapeutic efficiency by the CART cell strategy will also be investigated first using tumor xenograft mice models.

 

II. Immune Checkpoint Inhibitor CART cells therapy. Immune checkpoint inhibitor PD1/PD-L1 pathway plays an essential role in immune suppression in the tumor microenvironment and blockade of PD1/PD-L1 by monoclonal antibodies has been shown success in the treatment of several tumor types. We have developed different CARs strategies targeting PD1/PDL1 axis for further cell immunotherapy investigation. The goal is to eliminate tumor cells and build-up a potent immunotherapy protocols for clinical translation.

 

 

RESEARCH FOCUS AREA

Ovarian cancers, Pancreatic cancers, colon cancers, Immunotherapy, Immunomodulation, Ageing immunity

 

 

CONTACT US

Chao Lien Liu, Ph.D

Mail Stop: No. 250, Wu-Hsing Street, Taipei 11031, Taiwan

TEL: +886-2-2736-1661 ext: 3335

E-mail: chaolien@tmu.edu.tw

:::
最新消息
系所公告
活動與演講
招生訊息
獎學金公告
徵才訊息
系所簡介
醫學檢驗暨生物技術學系
醫學生物科技博士學位學程
歷屆系主任
核心能力
系所位置
檢驗醫學部
師資陣容
專任師資
兼任師資
客座教授
博士學程兼任師資
博士學程合聘專任師資
行政人員
研究發展
腫瘤基因調控研究室
基因剪輯與抗癌研究室
橋接實驗室
轉錄後調控研究室
李宏謨老師研究室
抗體及融合瘤核心實驗室
粒線體醫學與生殖醫學研究室
林景堉老師研究室
細菌致病因子之蛋白質結構與功能研究
吳雪霞老師研究室
劉兆蓮老師研究室
神經退化標誌研究室
課程資訊
特色課程
學士班
碩士班
醫學生物科技博士學位學程
國考資訊
職涯發展
招生資訊
學士班
研究所-碩士
研究所-博士
考生專區
國際學生
國際交流
國際合作機構
北海道大學
東京醫科齒科大學
九州大學
亞特蘭大兒童醫院
喬治亞洲立大學
捷克科學院
校友專區
校友會簡歷
校友會章程
校級傑出校友
辦法規章
學士班表單
碩士班表單
博士班表單
教育訓練
學生專區
活動花絮
職涯發展
醫檢師
國際醫檢師
出國進修
公職人員
司法人員(鑑試人員)
法務部調查局調查人員(化學鑑識組、醫學鑑識組)
胚胎師 (胚胎技術員)
細胞治療師
臨床試驗專員
生技產品專員
生技產業業務
研究助理
繼續升學
專利師
後西醫後中醫
聯絡我們